GTCpFE inhibits IKKα/β in the NF-κB pathway with anti-inflammatory activities and blocks p65 nuclear entry, which consists of Dimethyl fumarate (DMF) linked to Aspirin (ASA). GTCpFE exhibits selective anti-cancer stem-like cell (CSC) activity by reducing mammosphere growth and the CD44 + CD24 - immunophenotype. GTCpFE inhibits breast cancer stem cells , an important NFκB- and PGE2-dependent phenotype in aggressive cancers.